文献速递银屑病与炎症性皮肤病

选择性IL-23p19抑制剂治疗银屑病的安全性

Safety of selective IL-23p19 inhibitors for the treatment of psoriasis.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2019-06-27

本文综述已发表数据,比较tildrakizumab、guselkumab和risankizumab三种靶向IL-23p19的单克隆抗体与其他现有生物制剂在银屑病患者中的安全性。随机、安慰剂和阳性对照3期临床试验数据显示,这三种药物在中重度银屑病患者中具有有利的风险-获益特征,迄今未观察到显著安全性问题,最常见不良事件为上呼吸道感染。

要点

  • 3期数据显示IL-23p19抑制剂风险-获益有利,无显著安全性信号。
  • 最常见不良事件为上呼吸道感染。
  • 严重感染、恶性肿瘤、主要心血管不良事件率未增加。

核心结论

  • tildrakizumab、guselkumab和risankizumab在中重度银屑病患者中具有有利的风险-获益特征。
  • 迄今发表数据中未观察到这些IL-23p19抑制剂的显著安全性问题。

研究设计与样本

  • 本文综述已发表的随机、安慰剂和阳性对照3期临床试验数据,比较IL-23p19抑制剂与其他现有生物制剂在银屑病患者中的安全性。

主要发现

  • 3期研究中最常报告的不良事件为上呼吸道感染。
  • 未观察到严重感染、恶性肿瘤或主要心血管不良事件发生率增加。
  • 无信号提示机会性感染、活动性结核或潜伏结核再激活、皮肤黏膜念珠菌感染、炎症性肠病触发或加重、脱髓鞘疾病或自杀意念风险升高。

临床怎么用

  • 选择性靶向IL-23p19可能有助于避免其他作用机制生物制剂相关的不良事件。
  • 长期扩展研究和患者登记数据将进一步确定IL-23p19抑制剂在常规实践中治疗中重度银屑病的安全性特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Psoriasis is a chronic disease that requires long-term treatment. Consequently, understanding the safety and tolerability of any potential treatment over time is critical to effective prescribing. The biologic agents currently available for the treatment of psoriasis target a number of different inflammatory cytokines involved in psoriasis disease pathogenesis. The monoclonal antibodies tildrakizumab, guselkumab and risankizumab target the p19 subunit that is specific to interleukin (IL)-23. This article reviews published data on the safety of these IL-23p19 inhibitors in patients with psoriasis compared with other currently available biologic therapies. Data from randomized, placebo- and active-controlled phase 3 clinical trials show tildrakizumab, guselkumab and risankizumab to have a favourable risk-benefit profile in patients with moderate to severe psoriasis. No significant safety concerns have been observed for any of these IL-23p19 inhibitors in the data published to date. The most commonly reported adverse events (AEs) associated with these agents in phase 3 studies were upper respiratory tract infections. No increase was seen in rates of serious infections, malignancies or major adverse cardiovascular events, with no signals suggestive of an elevated risk of opportunistic infections, active tuberculosis or reactivation of latent tuberculosis infection, mucocutaneous Candida infections, triggering or worsening of inflammatory bowel disease, demyelinating disorders or suicidal ideation. Selectively targeting IL-23p19 may help avoid AEs that have been associated with biologic agents with other mechanisms of action. Data from long-term extension studies and patient registries will further establish the safety profile of IL-23p19 inhibitors for the treatment of moderate to severe psoriasis in routine practice.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Crowley JJ, Warren RB, Cather JC, et al. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2019. PMID: 31054215. doi:10.1111/jdv.15653

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。